New Individualized and Dynamic Therapeutic Strategies in DLGG

Hugues Duffau,Luc Taillandier

DOI: https://doi.org/10.1007/978-3-319-55466-2_28

2017-01-01

Abstract:Diffuse low-grade glioma (DLGG) is a chronic tumoral disease that ineluctably grows, migrates along white matter pathways, and progresses to higher grade of malignancy. Rather than a “wait and watch” policy, a therapeutic attitude is currently the gold standard, with early radical safe surgery as the first treatment. Indeed, intraoperative mapping in awake patients, with maximal resection up to functional boundaries, is significantly associated with a longer overall survival (OS), while preserving or even improving quality of life (QoL). However, most of traditional studies have investigated the impact of only one specific therapy (e.g. impact of surgery, or radiotherapy, or chemotherapy) on OS, without a comprehensive view of the whole management strategy on the patient’s cumulative time with preserved QoL versus time to malignant transformation. Here, our goal is to switch towards a more holistic concept, based on the anticipation of a personalized and long-term multistage therapeutic approach, with on-line adaptation of the strategy over years using feedback issued from clinical, radiological and histomolecular monitoring at the individual level. This dynamic and multistage approach challenges the classical strategy by proposing earlier therapy, by repeating treatments, and by reversing the traditional order of therapies (e.g. neoadjuvant chemotherapy if at least subtotal surgical resection is not possible, no early irradiation), to improve both OS and QoL. Neuro-oncologists should tailor their management strategy during the follow-up on the basis of real-time oncological control and functional outcome. Thus, we propose new personalized strategies dealing with the interactions between the natural course of DLGG, reaction neuroplasticity, and onco-functional modulation induced by serial treatments. The ultimate aim is taking measures to delay malignant transformation as long as possible, while giving DLGG patients a real life that includes planning for their long-term future (e.g. such as deciding whether to have a baby). This philosophy supports an individualized, functional, and preventive neurooncology.